RESEARCH FIELD

Chronopharmacology

Chronopharmacology investigates how the time of drug administration relative to biological rhythms — especially the 24-hour circadian clock — affects drug efficacy, toxicity, and pharmacokinetics. The field emerged from the recognition that nearly every aspect of drug disposition and target sensitivity oscillates with time of day, from cytochrome P450 enzyme expression in the liver to the activity rhythms of immune cells, tumour cells, and cardiovascular tissues. Chronotherapy — deliberately timing medication to match physiological rhythms — has demonstrated benefits for cancer chemotherapy, cardiovascular drugs including antihypertensives and statins, asthma treatments, and immunosuppressants. Researchers study how clock genes including BMAL1, CLOCK, and PERIOD regulate pharmacological targets, how shift work or jet lag disrupts drug response, and how wearable biosensors can personalise drug timing. Novel timed-release delivery systems and circadian biomarker-guided dosing are emerging clinical applications. The field is funded by pharmaceutical industry partnerships, oncology foundations, and circadian biology programmes.